Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer

Published:2021-09-01 Issue:9 Volume:7 Page:1333
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Tsakiridis Theodoros¹²³,Pond Gregory R.¹²⁴,Wright Jim¹²,Ellis Peter M.¹²,Ahmed Naseer⁵,Abdulkarim Bassam⁶,Roa Wilson⁷,Robinson Andrew⁸,Swaminath Anand¹²,Okawara Gordon¹²,Wierzbicki Marcin¹²,Valdes Mario⁹,Levine Mark¹²⁴

Affiliation:

1. Juravinski Cancer Center, Hamilton Health Science, Hamilton, Ontario, Canada

2. Department of Oncology, McMaster University, Hamilton, Ontario, Canada

3. Walker Family Cancer Center, St Catharines, Ontario, Canada

4. Ontario Clinical Oncology Group, Hamilton, Ontario, Canada

5. Cancer Care Manitoba, Winnipeg, Manitoba, Canada

6. McGill University, Montreal, Québec, Canada

7. Cross Cancer Institute, Edmonton, Alberta, Canada

8. Queen’s University, Kingston, Ontario, Canada

9. Grand River Cancer Center, Kitchener, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2782110/jamaoncology_tsakiridis_2021_oi_210039_1631288510.9927.pdf

Reference17 articles.

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non–small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.;Bradley;Lancet Oncol,2015

2. Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer.;Bradley;J Clin Oncol,2020

3. A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non–small cell lung cancer.;Sculier;Lung Cancer,2018

4. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.;Antonia;N Engl J Med,2018

5. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer.;Antonia;N Engl J Med,2017

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance;Cancer Letters;2024-09

2. Prognostic impact of metformin in solid cancer patients receiving immune checkpoint inhibitors: novel evidences from a multicenter retrospective study;Frontiers in Pharmacology;2024-07-29

3. Astragalus Polysaccharides and Metformin May Have Synergistic Effects on the Apoptosis and Ferroptosis of Lung Adenocarcinoma A549 Cells;Current Issues in Molecular Biology;2024-07-23

4. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

5. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments;Frontiers in Immunology;2024-06-26